Microbot Medical Reports Regulatory Submission for LIBERTY Endovascular Robotic System to the US FDA
Shots:
- Microbot Medical has submitted 510(k) premarket notification of LIBERTY Endovascular Robotic System to the US FDA, with the decision & launch, if approved, anticipated in Q2’25
- The submission was based on multi-center, single-arm, study assessing the efficiency & safety of LIBERTY in patients undergoing Peripheral Vascular Interventions
- LIBERTY, the first single-use disposable robotic system for endovascular procedures, eliminates bulky capital equipment, reduces radiation exposure, and improves ergonomics to ease physical strain on HCPs
Ref: Microbot Medical | Image: Microbot Medical
Related News:- Microbot Medical Reports Data from its GLP Pivotal Pre-Clinical Study
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
